Plasma humanin as a prognostic biomarker for canine myxomatous mitral valve disease: a comparison with plasma NT-roBNP.
Mangkhang. K K; Punyapornwithaya. V V; Tankaew. P P; Pongkan. W W; Chattipakorn. N N; Boonyapakorn. C C
Key Findings
- Dogs with myxomatous mitral valve disease have lower plasma humanin levels than healthy dogs.
- Lower humanin levels are linked to more severe heart‑failure stages (class B‑D).
- Humanin changes are detectable earlier than changes in the standard marker NT‑proBNP.
Practical Outcomes
- For biohackers, this study hints that humanin might be a sensitive indicator of early cardiac stress, but it’s currently only shown in dogs. It doesn’t provide dosing guidance or a ready‑to‑use protocol for humans, so more research is needed before considering humanin testing or supplementation for heart health.
Summary
In a study of 31 dogs with a common heart valve disease, researchers found that the blood level of the tiny protein humanin drops as the disease gets worse. The drop shows up earlier than the usual heart‑failure marker (NT‑proBNP), suggesting humanin could be a useful early warning sign for heart trouble.
Abstract
Myxomatous mitral valve disease (MMVD) is a cardiac condition commonly found in older dogs. The disease process can lead to heart failure (HF). In HF, an increase of reactive oxygen species (ROS) and abnormal mitochondrial activity, as well as apoptosis, have been reported. Humanin (HN) is a polypeptide that has a cardioprotective effect against apoptosis and oxidative stress. The purposes of this study were (1) to investigate the potential role of plasma HN as a cardiac biomarker to predict disease progression of MMVD, and (2) to compare plasma HN concentrations with plasma NT-pro BNP concentrations. Thirty-one dogs were included in the study. The dogs were separated into four groups: Group 1 was healthy dogs (n = 8), Group 2 was MMVD class B (n = 8), Group 3 was MMVD class C (n = 8), and Group 4 was MMVD class D (n = 7). All dogs were given a physical examination, thoracic radiography, echocardiography, and samples of their blood were collected for hematology and blood chemistry analysis. Levels of plasma HN and plasma NT-proBNP were also investigated. The results showed that plasma HN levels were lower in the dogs with MMVD and that lower plasma HN levels were associated with greater severity of MMVD-induced HF. It was possible to observe changes in plasma HN levels at a less severe disease stage than plasma NT-proBNP in dogs with MMVD. These findings sug- gest that a decreased plasma HN level can be used as a biomarker to identify dogs with MMVD-induced HF.
Study Information
pubmed
2018
2018-12-01T00:00:00.000Z
10.24425/124305
5